Compare · AMGN vs IKT
AMGN vs IKT
Side-by-side comparison of Amgen Inc. (AMGN) and Inhibikase Therapeutics Inc. (IKT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and IKT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $237.36B, about 1301.7x IKT ($182.4M).
- AMGN has been more active in the news (23 items in the past 4 weeks vs 4 for IKT).
- AMGN has more recent analyst coverage (25 ratings vs 8 for IKT).
- Company
- Amgen Inc.
- Inhibikase Therapeutics Inc.
- Price
- -
- -
- Market cap
- $237.36B
- $182.4M
- 1M return
- +0.18%
- -
- 1Y return
- +30.84%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2020
- News (4w)
- 23
- 4
- Recent ratings
- 25
- 8
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Inhibikase Therapeutics Inc.
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Latest AMGN
- Securitize Tokenizes Anthropic Stock Onchain on First Day of Public Trading
- AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE
- FDA Approval for KANJINTI issued to AMGEN INC
- Director Ishrak Omar was granted 152 shares, increasing direct ownership by 2% to 7,682 units (SEC Form 4)
- Director Holley Charles M was granted 185 shares, increasing direct ownership by 1% to 13,262 units (SEC Form 4)
- Director Gibbs David W was granted 278 shares (SEC Form 4)
- Director Drake Michael V was granted 114 shares, increasing direct ownership by 2% to 6,030 units (SEC Form 4)
- NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM
- Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated
- FDA Approval for AMJEVITA issued to AMGEN INC
Latest IKT
- SEC Form 10-Q filed by Inhibikase Therapeutics Inc.
- Inhibikase Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity
- Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026
- SEC Form 4 filed by Inhibikase Therapeutics Inc.
- SEC Form 3 filed by Inhibikase Therapeutics Inc.
- SEC Form 8-K filed by Inhibikase Therapeutics Inc.
- Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
- Chardan Capital Markets initiated coverage on Inhibikase Therapeutics with a new price target
- Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)